Phase 2 COPD Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Children and teenagers aged 2 years old up to (but not including) 18 years old at the time of signing the consent forms.
• People who have active, moderate to severe chronic graft-versus-host disease (a condition that can occur after a stem cell transplant) that requires treatment with medicines that suppress the immune system.
• People whose chronic graft-versus-host disease has not responded to treatment or has come back, and who have already been treated with at least 2 different systemic (whole-body) treatment courses, including steroids and a medicine called ruxolitinib.
• People who are already taking steroid medicines by mouth or injection, provided the dose has been stable for at least 2 weeks before the trial starts. Steroids applied to the skin or taken by inhaler are also permitted.
• People who are willing to be treated with one of a specific list of medicines at the start of the trial, which includes cyclosporine, tacrolimus, extracorporeal photopheresis (ECP), mycophenolate mofetil (MMF), everolimus, sirolimus, rituximab, imatinib, methotrexate, or ibrutinib (confirm with trial site which options apply).
• People who have previously received a stem cell transplant from a donor (related or unrelated, with any level of tissue matching), using any type of stem cell source, and with any type of pre-transplant preparation regimen.

Who may not be able to join:

• People who have had more than one prior donor stem cell transplant. (A previous transplant using the person's own stem cells is permitted.)
• People whose original blood disease has come back after the transplant, or who have received treatment specifically because the disease returned, including certain donor cell infusions given to treat relapse.
• People who have started taking cyclosporine, tacrolimus, or similar medicines (called CNIs or mTOR inhibitors) within 2 weeks before the trial start date.
• People with severely reduced kidney function or who are on dialysis due to kidney failure.
• People with significant liver problems (based on specific blood test results), unless those liver problems are caused by graft-versus-host disease affecting the liver.
• People with a history of inflammation of the pancreas (either short-term or long-term).
• People who currently have active and symptomatic muscle inflammation (myositis).
• Female adolescents who are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.